Table 1.
Baseline characteristics.
| Before administering SGLT2 inhibitor | After administering SGLT2 inhibitor | p‐value | |
|---|---|---|---|
| Number | 10 | 10 | |
| Age (years) | 67.8 ± 10.0 | ||
| Female (n, %) | 6 (60.0) | ||
| BMI (kg/m2) | 26.5 ± 4.8 | 25.6 ± 4.1 | 0.057 |
| eGFR (mL/min/1.73 m2) | 52.0 (44.2, 55.7) | 56.0 (44.7, 6152) | 0.101 |
| BNP (pg/mL) | 13.1 (7.9, 31.2) | 17.3 (11.6, 21.5) | 0.702 |
| 6MWD | 489.9 ± 80.2 | 568.3 ± 91.9 | 0.014 |
| Aetiology | |||
| Non‐PH | 1 (10) | ||
| Group 1 | 0 (0) | ||
| Group 2 | 0 (0) | ||
| Group 3 | 0 (0) | ||
| Group 4 | 8 (80) | ||
| Group 5 | 1 (10) | ||
| Medications (n, %) | |||
| Phosphodiesterase type 5 inhibitors | 0 (0) | ||
| sGC stimulator | 5 (50) | ||
| Endothelin receptor antagonists | 0 (0) | ||
| PGI2 receptor agonists | 1 (10) | ||
Note: Paired t‐tests were used for the changes in the patients before and after treatment with SGLT2 inhibitor.
Abbreviations: BMI, body mass index; BNP, brain natriuretic peptide; eGFR, estimated glomerular filtration rate; 6MWD, 6‐min walking distance; PG12, prostaglandin I2; PH, pulmonary hypertension, sGC, soluble guanylate cyclase.